Erratum: Cardiac biomarkers: a contemporary status report
Reads0
Chats0
TLDR
In the January 2006 issue, the footnote to Table 1 was published as “aN-terminal pro-brain natriuretic peptide has yet to be approved by the FDA for risk-stratification purposes in acute coronary syndromes”.Abstract:
Corrigendum In the January 2006 issue, the footnote to Table 1 was published as “aN-terminal pro-brain natriuretic peptide has yet to be approved by the FDA for risk-stratification purposes in acute coronary syndromes”. This should have appeared as “aN-terminal pro-brain natriuretic peptide has beenapproved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for risk-stratification purposes in patients with stable coronary artery disease”.read more
Citations
More filters
Journal ArticleDOI
Evaluation of changes in cardiac biomarker concentrations and enzyme activities in serum after short- and long-duration transcutaneous cardiac pacing in dogs.
TL;DR: Serum concentrations of creatine kinase-MB fraction and cardiac troponin I and activities of aspartate transaminase, creatine kinases, and lactate dehydrogenase should be more carefully monitored after TCP of > 1 hour's duration to evaluate potential myocardial damages.
Related Papers (5)
Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes.
de Lemos Ja,David A. Morrow +1 more
Individualizing therapy in acute coronary syndromes: Using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy
Vivian Y. Mo,James A. de Lemos +1 more